<DOC>
	<DOCNO>NCT01635777</DOCNO>
	<brief_summary>Miltefosine efficacy &gt; 85 %</brief_summary>
	<brief_title>Safety Efficacy Oral Miltefosine Patients With Post Kala Azar Dermal Leishmaniasis ( PKDL )</brief_title>
	<detailed_description />
	<mesh_term>Miltefosine</mesh_term>
	<criteria>12 year old nodule papule consistent post kalaazar dermal leishmaniasis parasitological confirmation Leishmania infection platelet count &lt; 100x 109/l , leukocyte count &lt; 2.5 x 109/l , hemoglobin &lt; 8.0 g/100 ml , liver function test &gt; 3 time upper limit normal range , bilirubin &gt; 2 time upper limit normal range , serum creatinine blood urea nitrogen &gt; 1.5 time upper limit normal range ) ; noncompensated uncontrolled condition , lactation , pregnancy , likelihood inadequate contraception female childbearing potential treatment period plus 2 month thereafter ; treatment antileishmanial drug within previous 12 week .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>PKDL</keyword>
	<keyword>miltefosine</keyword>
</DOC>